Abstract
Introduction and aim: Early symptomatic osteoarthritis (OA) of the knee poses a difficult challenge to orthopaedic surgeons, particularly in the presence of malalignment. Most surgical options are palliative. Our aim was to assess combined high tibial osteotomy (HTO) and matrix-induced autologous chondrocyte implantation (MACI) as a curative option.
Methods Patients with localised medial compartment OA and varus malalignment were identified. Suitability for the above procedure was confirmed at arthroscopy and specimen taken for culture. HTO and MACI procedures were performed in one sitting by a single surgeon. Patients received three months rehabilitation and function was assessed preoperatively and at three-monthly intervals.
Results Twelve patients were identified: nine male; average age 46 years (27–58). Mean varus deformity was 6 degrees. Two patients also had evidence of osteochondritis dissecans, and two early patello-femoral OA. Eight patients had had previous surgery to the knee.
Eleven patients had a lateral closing wedge osteotomy; the medial opening wedge was performed in a case of leg shortening. Mean operation duration was 72 minutes (60–90). The graft was fixed with fibrin glue in all cases, and augmented with stitches or vicryl pins in five cases. Mean defect size was 6.2cm2 (2–12). There were three complications: one DVT, a haemarthrosis and a graft detachment.
Average follow-up was 16 months. MRI scans at three months show oedematous tissue at the defect sites, contrasting with the fluid filled defects seen preoperatively. Scans at one-year show hyaline-like cartilage infill with similar signal characteristics to native hyaline cartilage. Six minute walk test and knee injury and osteoarthritis outcome score indicate significantly improved functional capacity at six months and one year.
Conclusions Preliminary results suggest combined HTO and MACI is successful for young patients with early OA associated with malalignment.
Theses abstracts were prepared by Professor Roger Lemaire. Correspondence should be addressed to EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.
